Novel |
BCL3 |
BCL3 transcription coactivator |
|
|
|
Novel |
DPF2 |
double PHD fingers 2 |
|
|
|
Novel |
ITGB3BP |
integrin subunit beta 3 binding protein |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- NRIF signals cell death from the nucleus
- NRIF signals cell death from the nucleus
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- RHO GTPases Activate Formins
- Deposition of new CENPA-containing nucleosomes at the centromere
- Mitotic Prometaphase
- EML4 and NUDC in mitotic spindle formation
|
|
|
Novel |
MAP4K2 |
mitogen-activated protein kinase kinase kinase kinase 2 |
|
|
|
Novel |
PGA5 |
pepsinogen A5 |
|
|
|
Novel |
PPP1CA |
protein phosphatase 1 catalytic subunit alpha |
- Triglyceride catabolism
- DARPP-32 events
- Downregulation of TGF-beta receptor signaling
- Circadian Clock
|
- 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid
|
|
Novel |
RAB11A |
RAB11A, member RAS oncogene family |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Vasopressin regulates renal water homeostasis via Aquaporins
- Anchoring of the basal body to the plasma membrane
- VxPx cargo-targeting to cilium
- TBC/RABGAPs
- RAB geranylgeranylation
|
- 5'-Guanosine-Diphosphate-Monothiophosphate
- Guanosine-5'-Diphosphate
|
|
Novel |
RBM4 |
RNA binding motif protein 4 |
|
|
|
Novel |
SLC3A2 |
solute carrier family 3 member 2 |
- Basigin interactions
- Amino acid transport across the plasma membrane
- Defective SLC7A7 causes lysinuric protein intolerance (LPI)
- Tryptophan catabolism
|
|
|
|
AATF |
apoptosis antagonizing transcription factor |
- NRAGE signals death through JNK
|
|
|
|
ACTL6A |
actin like 6A |
- HATs acetylate histones
- RMTs methylate histone arginines
- UCH proteinases
- DNA Damage Recognition in GG-NER
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
|
|
|
|
AGO1 |
argonaute RISC component 1 |
- Pre-NOTCH Transcription and Translation
- MicroRNA (miRNA) biogenesis
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- Ca2+ pathway
- Small interfering RNA (siRNA) biogenesis
- Post-transcriptional silencing by small RNAs
- Transcriptional regulation by small RNAs
- TP53 Regulates Metabolic Genes
- MAPK6/MAPK4 signaling
- Transcriptional Regulation by VENTX
- Regulation of RUNX1 Expression and Activity
- RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
- Regulation of PTEN mRNA translation
- Competing endogenous RNAs (ceRNAs) regulate PTEN translation
- Transcriptional Regulation by MECP2
- Transcriptional Regulation by MECP2
- Estrogen-dependent gene expression
- Regulation of MECP2 expression and activity
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
|
|
|
|
AHR |
aryl hydrocarbon receptor |
- PPARA activates gene expression
- Phase I - Functionalization of compounds
- Endogenous sterols
- Xenobiotics
- Aryl hydrocarbon receptor signalling
|
- Omeprazole
- Mexiletine
- Nimodipine
- Flutamide
- Atorvastatin
- Leflunomide
- Ginseng
- Indirubin-3'-monoxime
- Resveratrol
- Quercetin
- beta-Naphthoflavone
- Emodin
- 1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine
- Diosmin
- Indigotindisulfonic acid
- Kynurenic Acid
- Epigallocatechin gallate
- Cantharidin
- Indirubin
|
|
|
AKAP8 |
A-kinase anchoring protein 8 |
|
|
|
|
APBA2 |
amyloid beta precursor protein binding family A member 2 |
- Neurexins and neuroligins
|
|
|
|
AR |
androgen receptor |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Ub-specific processing proteases
- RUNX2 regulates osteoblast differentiation
- RUNX2 regulates osteoblast differentiation
|
- Diethylstilbestrol
- Levonorgestrel
- Progesterone
- Spironolactone
- Flutamide
- Oxandrolone
- Fluphenazine
- Testosterone
- Mitotane
- Estrone
- Nilutamide
- Tamoxifen
- Norethisterone
- Drostanolone
- Norgestimate
- Nandrolone phenpropionate
- Ketoconazole
- Acetophenazine
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone propionate
- Oxybenzone
- 1-Testosterone
- Boldenone
- Calusterone
- Periciazine
- Prasterone
- Flufenamic acid
- Stanolone
- (R)-Bicalutamide
- Metribolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone acetate
- LGD2941
- Dimethylcurcumin
- Oxymetholone
- Methyltestosterone
- Norelgestromin
- Stanozolol
- Tetrahydrogestrinone
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- BMS-564929
- S-23
- phenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- Andarine
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- LGD-2226
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Triclosan
- Nandrolone decanoate
- Ulipristal
- Enzalutamide
- Eugenol
- Dienogest
- Norethynodrel
- Norgestrel
- Homosalate
- Enzacamene
- Mibolerone
- Phenothiazine
- Gestrinone
- Apalutamide
- Clascoterone
- Darolutamide
- Esculin
- Ligandrol
- Testosterone cypionate
- Testosterone enanthate
- Testosterone undecanoate
- Stanolone acetate
- Segesterone acetate
- Boldenone undecylenate
- Echinacoside
- Ketodarolutamide
|
- 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
- 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
- Prostate cancer
- Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
|
|
ARNT |
aryl hydrocarbon receptor nuclear translocator |
- Regulation of gene expression by Hypoxia-inducible Factor
- PPARA activates gene expression
- Phase I - Functionalization of compounds
- Endogenous sterols
- Xenobiotics
- Aryl hydrocarbon receptor signalling
|
|
|
|
ASB9 |
ankyrin repeat and SOCS box containing 9 |
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
AURKA |
aurora kinase A |
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Regulation of PLK1 Activity at G2/M Transition
- SUMOylation of DNA replication proteins
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Regulation of TP53 Activity through Phosphorylation
- FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
- AURKA Activation by TPX2
- Interaction between PHLDA1 and AURKA
|
- Phosphonothreonine
- AT9283
- CYC116
- Alisertib
- SNS-314
- Cenisertib
- Enzastaurin
- 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
- AKI-001
- 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
- 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
- N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
- N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
- 2-(1H-pyrazol-3-yl)-1H-benzimidazole
- N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
- Fostamatinib
- MLN8054
|
|
|
BANP |
BTG3 associated nuclear protein |
- Regulation of TP53 Activity through Association with Co-factors
|
|
|